Krystal Biotech, Inc. (NASDAQ:KRYS) Given Consensus Rating of “Buy” by Brokerages

Krystal Biotech, Inc. (NASDAQ:KRYS) has received a consensus recommendation of “Buy” from the nine brokerages that are covering the firm, Marketbeat reports. Nine investment analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have covered the stock in the last year is $171.00.

Several equities analysts have recently weighed in on the company. Citigroup lifted their price target on Krystal Biotech from $160.00 to $195.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. Guggenheim upped their price target on Krystal Biotech from $130.00 to $175.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. William Blair restated an “outperform” rating on shares of Krystal Biotech in a research report on Tuesday, February 27th. HC Wainwright reaffirmed a “buy” rating and set a $200.00 price objective on shares of Krystal Biotech in a research note on Monday, April 22nd. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $204.00 target price (up from $178.00) on shares of Krystal Biotech in a research note on Tuesday, April 16th.

Krystal Biotech Stock Down 3.1 %

Krystal Biotech stock opened at $153.12 on Friday. The stock has a market cap of $4.37 billion, a P/E ratio of 1,914.24 and a beta of 0.85. The company’s 50 day moving average price is $166.04 and its two-hundred day moving average price is $132.43. Krystal Biotech has a 52 week low of $82.09 and a 52 week high of $189.97.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, February 26th. The company reported $0.30 EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.82. The company had revenue of $42.14 million during the quarter, compared to the consensus estimate of $27.43 million. During the same period last year, the firm posted ($1.25) EPS. On average, equities analysts anticipate that Krystal Biotech will post 1.89 EPS for the current year.

Insider Activity

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Monday, March 11th. The stock was sold at an average price of $170.96, for a total value of $4,274,000.00. Following the completion of the sale, the insider now owns 1,550,882 shares of the company’s stock, valued at approximately $265,138,786.72. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Krystal Biotech news, CAO Kathryn Romano sold 5,000 shares of the business’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $165.88, for a total transaction of $829,400.00. Following the completion of the sale, the chief accounting officer now directly owns 12,936 shares in the company, valued at approximately $2,145,823.68. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the sale, the insider now directly owns 1,550,882 shares of the company’s stock, valued at $265,138,786.72. The disclosure for this sale can be found here. Insiders have sold a total of 38,087 shares of company stock worth $6,210,591 over the last 90 days. 14.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Krystal Biotech

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new position in shares of Krystal Biotech in the third quarter worth $2,429,000. Handelsbanken Fonder AB lifted its stake in Krystal Biotech by 5.2% in the 3rd quarter. Handelsbanken Fonder AB now owns 112,800 shares of the company’s stock worth $13,085,000 after purchasing an additional 5,600 shares in the last quarter. Commonwealth Equity Services LLC boosted its holdings in shares of Krystal Biotech by 2.5% during the 3rd quarter. Commonwealth Equity Services LLC now owns 4,426 shares of the company’s stock valued at $513,000 after purchasing an additional 110 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Krystal Biotech by 1.7% during the third quarter. Bank of New York Mellon Corp now owns 98,220 shares of the company’s stock valued at $11,394,000 after purchasing an additional 1,604 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Krystal Biotech by 11.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,487 shares of the company’s stock worth $520,000 after purchasing an additional 452 shares during the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).